PHIA Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Recurring Services & Installed BasePhilips’ mix of capital equipment plus attached services, software and consumables creates a durable installed‑base flywheel. This generates higher‑margin, repeatable revenue, increases customer switching costs and stabilizes cash flows relative to one‑off equipment cycles, supporting medium‑term margin and revenue visibility.
Regulatory & Innovation MomentumA steady stream of regulatory approvals and new product launches (AI cardiac MR, spectral CT, helium‑free MR initiatives) reduces commercialization risk and strengthens Philips’ technology moat. Continuous regulatory wins accelerate clinical adoption, improve attach rates for software/services, and underpin sustainable equipment demand over the medium term.
Productivity & Margin RecoveryMaterial productivity delivery and observable margin expansion demonstrate structural cost discipline. On‑track savings toward a multi‑year €1.5bn target improve operating leverage, support management’s mid‑cycle margin ambitions and enhance free cash generation potential, strengthening balance‑sheet flexibility and funding for strategic reinvestment.
Bears Say
Unresolved Legal RiskOutstanding Respironics‑related proceedings represent a potentially material, unmodeled liability. Their exclusion from guidance creates persistent uncertainty around future earnings and cash flows, complicates capital allocation decisions and may constrain shareholder returns or M&A until the legal exposure is resolved or more clearly quantified.
Volatile Cash GenerationPhilips’ historical cash‑flow volatility—including negative operating/FCF years and a sharp 2025 FCF decline versus 2024—reduces confidence in sustainable internal funding. Variable FCF makes it harder to predict capacity for capex, R&D, services investments or discretionary returns, increasing reliance on disciplined balance‑sheet management.
China Procurement HeadwindsRising centralized procurement in China is structurally pressuring pricing and order conversion in key modalities (ultrasound, CT). Given China’s scale, persistent procurement‑driven pricing and longer decision cycles can limit equipment growth and margin recovery in diagnostic segments, dampening a significant market opportunity over the medium term.
Koninklijke Philips News
PHIA FAQ
What was Koninklijke Philips N.V.’s price range in the past 12 months?
Currently, no data Available
What is Koninklijke Philips N.V.’s market cap?
Koninklijke Philips N.V.’s market cap is CHF21.46B.
When is Koninklijke Philips N.V.’s upcoming earnings report date?
Koninklijke Philips N.V.’s upcoming earnings report date is Jul 28, 2026 which is in 17 days.
How were Koninklijke Philips N.V.’s earnings last quarter?
Koninklijke Philips N.V. released its earnings results on May 06, 2026. The company reported $0.218 earnings per share for the quarter, beating the consensus estimate of $0.186 by $0.032.
Is Koninklijke Philips N.V. overvalued?
According to Wall Street analysts Koninklijke Philips N.V.’s price is currently Undervalued.
Does Koninklijke Philips N.V. pay dividends?
Koninklijke Philips N.V. does not currently pay dividends.
What is Koninklijke Philips N.V.’s EPS estimate?
Koninklijke Philips N.V.’s EPS estimate is 0.32.
How many shares outstanding does Koninklijke Philips N.V. have?
Currently, no data Available
What happened to Koninklijke Philips N.V.’s price movement after its last earnings report?
Koninklijke Philips N.V. reported an EPS of $0.218 in its last earnings report, beating expectations of $0.186. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Koninklijke Philips N.V.?
Currently, no hedge funds are holding shares in CH:PHIA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Koninklijke Philips Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
16.69%
12-Months-Change
Fundamentals
Return on Equity
8.96%
Trailing 12-Months
Asset Growth
7.05%
Trailing 12-Months
Company Description
Koninklijke Philips N.V.
Koninklijke Philips NV is a technology company, which engages in the healthcare, lighting, and consumer well-being markets. It operates through the following segments: Diagnosis and Treatment; Connected Care; Personal Health; and Other. The Diagnosis and Treatment segment consists of systems, smart devices, software, and services, powered by AI-enabled solutions that support precision diagnoses and minimally invasive treatment in therapeutic areas such as cardiology, peripheral vascular, neurology, surgery, and oncology. The Connected Care segment focuses on Hospital Patient Monitoring, Sleep and Respiratory Care, and Enterprise Informatics. The Personal Health segment represents Oral Healthcare business unit, Personal Care business unit, and Mother and Child Care business unit. The Other segment is involved on the Innovation and Strategy, IP Royalties, Central costs, and other small items. The company was founded by Anton Frederik Philips and Gerard Leonard Frederik Philips in 1891 and is headquartered in Amsterdam, the Netherlands.
PHIA Company Deck
PHIA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call presented a constructive tone: Philips reported broad-based order and sales growth, margin expansion, strong productivity delivery, robust innovation and regulatory momentum, and meaningful balance sheet improvement. These positives were balanced against notable headwinds in China (centralized procurement), cost inflation (freight, components, plastics) and near-term margin timing effects from tariffs and inflation. Management reiterated full-year guidance (3%–4.5% comparable sales; 12.5%–13% adjusted EBITDA margin; EUR 1.3–1.5bn free cash flow) and emphasized mitigation actions (productivity, selective pricing, AI-enabled cost savings) while acknowledging geopolitical and legal uncertainties.View all CH:PHIA earnings summariesOptions Prices
Currently, No data available
---